During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen ...

Solid tumours are often heterogeneous, they contain a diverse range of cancer cells with varying characteristics ...

T-cell therapy has increased rapidly, the clinical benefit seen with these products comes at a cost for patients who experience toxicities related to the induction of a powerful immune response. The ...

For more information, please refer to the full article in JAMA Oncology.

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the ...

The therapy is currently in Phase I/Ib clinical development for patients with relapsed/refractory multiple myeloma.

For many doctors and researchers, immunotherapy that uses someone’s own immune system to target and attack cancer cells is the next and best frontier of cancer treatment.

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has broadened its collaboration with Moderna, Inc. (Nasdaq: MRNA) ...

Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, ...

Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell (CAR T) and T ...